tislelizumab
beigene,novartis
ph iii study of tislelizumab vs. soc in 1l treatment of scc esophageal cancer adds 6.6 mo in os in all randomized pts. #wcgic2022 #myesmo #cancer #esmo 
Doctor of Medicine, resident doctor, GI cancers @ National Cancer Institute in Bratislava, Slovakia. PhD candidate(3rd year) Faculty of Medicine @ComeniusUni